Hepatocyte CYR61 polarizes profibrotic macrophages to orchestrate NASH fibrosis
- Sci Transl Med. 2023 Sep 27;15(715):eade3157. doi: 10.1126/scitranslmed.ade3157.
- 1. Department of Cellular and Molecular Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
- 2. Section of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Yale School of Medicine, New Haven, CT 06514, USA.
- 3. Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06514, USA.
- 4. Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
- 5. Pittsburgh Liver Research Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
- 6. Kadmon Corporation LLC, 450 East 29th Street, New York, NY 10016, USA.
- 7. Department of Comparative Medicine, Yale School of Medicine, New Haven, CT 06514, USA.
- 8. Section of Neonatology, Department of Pediatrics, Yale School of Medicine, New Haven, CT 06514, USA.
- 9. Department of Cellular and Molecular Physiology, Yale School of Medicine, New Haven, CT 06514, USA.
- 10. Yale Liver Center, Yale School of Medicine, New Haven, CT 06514, USA.
Obesity is increasing worldwide and leads to a multitude of metabolic diseases, including Cardiovascular Disease, type 2 diabetes, nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis (NASH). Cysteine-rich angiogenic inducer 61 (CYR61) is associated with the progression of NASH, but it has been described to have anti- and proinflammatory properties. We sought to examine the role of liver CYR61 in NASH progression. CYR61 liver-specific knockout mice on a NASH diet showed improved glucose tolerance, decreased liver inflammation, and reduced fibrosis. CYR61 polarized infiltrating monocytes promoting a proinflammatory/profibrotic phenotype through an IRAK4/Syk/NF-κB signaling cascade. In vitro, CYR61 activated a profibrotic program, including PDGFa/PDGFb expression in macrophages, in an IRAK4/Syk/NF-κB-dependent manner. Furthermore, targeted-antibody blockade reduced CYR61-driven signaling in macrophages in vitro and in vivo, reducing fibrotic development. This study demonstrates that CYR61 is a key driver of liver inflammation and fibrosis in NASH.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: NF-κB